Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 145.24

-1.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Xavier who wrote (62)	12/1/1997 1:59:00 PM
From: JAL	Read Replies (1) of 1834

Neurocrine Biosciences To Begin Trials For MS, Diabetes Drug NEW YORK (Dow Jones)--Neurocrine Biosciences Inc. (NBIX) said it expects to initiate large Phase II and Phase III clinical trials for its altered peptide ligands, or APL, for treating multiple sclerosis and Type I diabetes in 1998. In a presentation at BancAmerica Robertson Stephens' medical conference here Monday, company President and Chief Executive Gary Lyons said the company also expects to initiate human trials for its corticotropin releasing factor, or CRF, for the treatment of depression and stroke. Lyons said the company expects to remain profitable and will end the year with $77 million to $80 million in cash. Lyons also said the company plans to advance two more products in 1998 for which it will start consuming some of that cash. He said the company is cash sufficient until 2001.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next